映恩生物-B(09606.HK) 公布2025年度业绩,收入录得18.52亿人民币(下同),按年下降4.6%。亏损由上年度10.5亿元,扩至25.95亿元,每股亏损39.8元。不派末期息。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-23 16:25。)过往派息公布日期派息事项派息内容2025/08/26中期业绩无派息AASTOCKS新闻
Source Link映恩生物-B(09606.HK) 公布2025年度业绩,收入录得18.52亿人民币(下同),按年下降4.6%。亏损由上年度10.5亿元,扩至25.95亿元,每股亏损39.8元。不派末期息。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-23 16:25。)过往派息公布日期派息事项派息内容2025/08/26中期业绩无派息AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.